Table 1 Baseline characteristics of patients
All patients (N = 15) | |
|---|---|
Age, yr, median [IQR] | 44 [36.5–63.5] |
Female sex (%) | 15 (100.0 %) |
Disease duration, yr, median [IQR] | 1 [0.5–6.5] |
Whole unstimulated salivary flow (<0.1 ml/min) | 12 (80 %) |
Schirmer’s test ≤5 mm | 10 (66.7 %) |
Focus score ≥1 | 12 (80 %) |
Baseline focus score, median [IQR] | 1.6 [1–2.4] |
Anti-SSA antibodies | 14 (93.3 %) |
Anti-SSB antibodies | 10 (66.7 %) |
Current background medication | |
Corticosteroids | 4 (26.7 %) |
Hydroxychloroquine | 5 (33.3 %) |
Methotrexate | 0 (0 %) |
Reason for inclusion | |
Systemic complications | 11 (73.3 %) |
Recent-onset disease | 4 (26.7 %) |
Increase in B-cell biomarker values | 11 (73.3 %) |
ESSDAI score (0–123), median [IQR] | 7 [3–11] |
ESSPRI score (0–10), median [IQR] | 6.33 [6–7.33] |